Squarepoint Ops LLC Grows Stake in Compass Therapeutics, Inc. $CMPX

Squarepoint Ops LLC lifted its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 1,906.9% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,007,507 shares of the company’s stock after acquiring an additional 957,305 shares during the period. Squarepoint Ops LLC’s holdings in Compass Therapeutics were worth $2,206,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Compass Therapeutics in the second quarter valued at $71,000. California State Teachers Retirement System lifted its holdings in Compass Therapeutics by 32.0% in the second quarter. California State Teachers Retirement System now owns 148,291 shares of the company’s stock valued at $325,000 after acquiring an additional 35,975 shares during the last quarter. HB Wealth Management LLC purchased a new position in shares of Compass Therapeutics during the 2nd quarter worth approximately $29,000. AXQ Capital LP grew its stake in shares of Compass Therapeutics by 68.1% in the second quarter. AXQ Capital LP now owns 42,118 shares of the company’s stock valued at $92,000 after buying an additional 17,060 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in Compass Therapeutics during the 2nd quarter worth approximately $64,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CMPX has been the topic of several recent analyst reports. Citigroup reiterated a “market outperform” rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Wall Street Zen lowered Compass Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. LADENBURG THALM/SH SH started coverage on shares of Compass Therapeutics in a report on Wednesday, July 1st. They issued a “buy” rating and a $5.00 price target on the stock. Piper Sandler raised their price objective on Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Stifel Nicolaus set a $6.00 price objective on shares of Compass Therapeutics in a report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.77.

Compass Therapeutics Price Performance

CMPX opened at $1.96 on Tuesday. The company’s 50 day moving average price is $2.21 and its two-hundred day moving average price is $3.12. Compass Therapeutics, Inc. has a fifty-two week low of $1.61 and a fifty-two week high of $6.88. The firm has a market capitalization of $352.98 million, a price-to-earnings ratio of -4.90 and a beta of 0.95.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, equities research analysts predict that Compass Therapeutics, Inc. will post -0.47 EPS for the current year.

Compass Therapeutics Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.